Capsulomics, announces official rebrand as Previse and launches their first product to enable accurate prognosis and detection data for those prone to Esophageal Cancer.
BALTIMORE, March 21, 2023 /PRNewswire/ — Previse, formerly known as Capsulomics, Inc., announced that the company has closed a $3M seed round and launched its first laboratory-developed test, Esopredict™.
Esophageal cancer is one of the most lethal cancers in the world, with a 20% five-year survival rate after diagnosis. According to the American Cancer Society, in 2023, about 21,560 new US cases of esophageal cancer will be diagnosed, and 16,120 people will die from the disease. To improve survival, it is critical to know which patients with the precursor to esophageal cancer, Barrett’s esophagus, will progress to having high-grade dysplasia or esophageal cancer in the future.